Swarthmore College

Psychology Faculty Works

Psychology

10-1-2019

Examining Military Population And Trauma Type As Moderators Of Treatment Outcome For First-Line Psychotherapies For PTSD: A Meta-Analysis

C. L. Straud

Jedidiah Siev Swarthmore College, jsiev1@swarthmore.edu

S. Messer

A. K. Zalta

Follow this and additional works at: https://works.swarthmore.edu/fac-psychology

Part of the Psychology Commons Let us know how access to these works benefits you

Recommended Citation

C. L. Straud, Jedidiah Siev, S. Messer, and A. K. Zalta. (2019). "Examining Military Population And Trauma Type As Moderators Of Treatment Outcome For First-Line Psychotherapies For PTSD: A Meta-Analysis". *Journal Of Anxiety Disorders*. Volume 67, DOI: 10.1016/j.janxdis.2019.102133 https://works.swarthmore.edu/fac-psychology/1086

This work is brought to you for free by Swarthmore College Libraries' Works. It has been accepted for inclusion in Psychology Faculty Works by an authorized administrator of Works. For more information, please contact myworks@swarthmore.edu.



HHS Public Access

JAnxiety Disord. Author manuscript; available in PMC 2020 October 01.

Published in final edited form as:

Author manuscript

J Anxiety Disord. 2019 October; 67: 102133. doi:10.1016/j.janxdis.2019.102133.

Examining military population and trauma type as moderators of treatment outcome for first-line psychotherapies for PTSD: A meta-analysis

Casey L. Straud, Psy.D.^a, Jedidiah Siev, Ph.D.^b, Stephen Messer, Ph.D.^c, Alyson K. Zalta, Ph.D.^d

^aUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

^bSwarthmore College, Swarthmore, Pennsylvania, United States

^cNova Southeastern University, Fort Lauderdale, Florida, United States

^dUniversity of California, Irvine, Irvine, California, United States

Abstract

There is conflicting evidence as to whether military populations (i.e., veteran and active-duty military service members) demonstrate a poorer response to psychotherapy for posttraumatic stress disorder (PTSD) compared to civilians. Existing research may be complicated by the fact that treatment outcomes differences could be due to the type of trauma exposure (e.g., combat) or population differences (e.g., military culture). This meta-analysis evaluated PTSD treatment outcomes as a function of trauma type (combat v. assault v. mixed) and population (military v. civilian). Unlike previous meta-analyses, we focused exclusively on manualized, first-line psychotherapies for PTSD as defined by expert treatment guidelines. Treatment outcomes were large across trauma types and population; yet differences were observed between trauma and population subgroups. Military populations demonstrated poorer treatment outcomes compared to civilians. The combat and assault trauma subgroups had worse treatment outcomes compared to the mixed trauma subgroup, but differences were not observed between assault and combat subgroups. Higher attrition rates predicted poorer treatment outcomes, but did not vary between military populations and civilians. Overall, manualized, first-line psychotherapies for PTSD should continue to be used for civilians and military populations with various trauma types. However, greater emphasis should be placed on enhancing PTSD psychotherapies for military populations and on treatment retention across populations based on findings from this metaanalysis.

Keywords

Meta-Analysis; Posttraumatic stress disorder; First-Line Treatments; Trauma type; Military; Veterans; Civilians

Correspondence concerning this article should be addressed to Casey Straud, Department of Psychiatry, University of Texas Health Science Center at San Antonio, 7550 Interstate Highway 10 West, Suite 1325, San Antonio, TX 78229, United States. Phone: 210-562-6742; straud@uthscsa.edu.

1. Introduction

Posttraumatic stress disorder (PTSD) is a debilitating condition that leads to relationship dysfunction, physical health issues, greater health care utilization, increased work sick days, substance abuse, and elevated suicidality risk (Hoge, Terhakopian, Castro, Messer, & Engel, 2007; Taft, Watkins, Stafford, Street, & Monson, 2011; Thomas et al., 2010). Research has shown particularly high rates of PTSD in military populations (13–30%; Thomas et al., 2010; Kok, Herrell, Thomas & Hoge, 2012) compared to the general population (6–8%; Kessler, Berglund, Demler, Jin, & Walters, 2005). Given that almost 3 million U.S. military personnel have deployed to the Middle East and surrounding territories since 2001, the demand for effective treatments for veterans and active-duty service members, hereinafter referred to as military populations, is critical.

Evidence based psychotherapies for PTSD exist and the positive effects of evidence-based psychotherapies in civilian and military populations are well-established (Bisson et al., 2007; Bradley, Greene, Russ, Dutra & Western, 2005; Cusack et al., 2016; Goodson, Helstrom, Halpern, Ferenschack, & Gillihan, 2011; Kline, Cooper, Rytwinksi, & Feeny, 2018; Powers, Halpern, Ferenshak, Gilliahn, & Foa, 2010; Steenkamp, Litz, Hoge, & Marmar, 2015). However, several meta-analyses have reported smaller effect sizes among treatment studies with a greater proportion of veterans and combat samples (Bisson et al., 2007; Bradley et al., 2005; Sloan, Feinstein, Gallagher, Beck, & Keane, 2013; Watts, et al., 2013). These findings suggest military populations experience less benefit from psychotherapies for PTSD compared to civilians (Litz et al., 2009; Sifferlin, 2015; Steenkamp et al., 2015). Yet, existing meta-analyses have been limited in evaluating treatment response differences among military and civilian populations in several ways. For example, Bisson et al. (2007) only evaluated two studies of Vietnam veterans. Sloan et al. (2013) found that group interventions for PTSD were not significantly superior to active control conditions (d = 0.09); however, they did not include individual interventions. Watts et al. (2013) found that studies with more women, or fewer veterans, had larger effect sizes, but the authors were unable to disentangle whether this finding was due to gender or veteran status. Additionally, Watts et al. (2013) included psychotherapies that were considered to be first-line and non-first-line treatments according to PTSD treatment recommendation guidelines, which may have confounded results (American Psychological Association [APA], 2017; Department of Veterans Affairs and Department of Defense [VA/DoD], 2017; Foa, Keane, Friedman, & Cohen, 2009; Institute of Medicine [IOM], 2008; International Society for Traumatic Stress Studies [ISTSS], 2018). Similarly, Bradley et al. (2005) included all psychotherapies in their meta-analysis. They also reported that trauma type was a predictor of treatment effect size, but only reported an omnibus test of differences across three groups (combat v. mixed v. assault). This study did not test whether the combat group, which demonstrated the smallest effect size, was significantly different from the other groups.

There is also meta-analytic evidence to suggest that military populations benefit equally well from PTSD treatments compared to civilians. In a recent meta-analysis, Kline et al. (2018) demonstrated that population type (i.e., military v. civilian) was unrelated to effect sizes at long-term follow-up. However, this meta-analysis also included non-first-line psychotherapy

treatments and only examined effect sizes at long-term follow-up, excluding studies that did not provide follow-up data. Thus, whether or not military populations demonstrate a poorer treatment response from first-line PTSD psychotherapies in comparison to their civilian counterparts remains an open and important question.

Conflicting findings in the existing research literature among military and civilian populations may be complicated by differences in the nature of the trauma exposure (e.g., combat v. assault) or differences in the patient population (i.e., characteristics of military v. civilian populations). Research has shown that military populations experience traumatic events at a greater frequency, these events are often combat-related, and are often more severe and diverse compared to civilian populations (Green et al., 2015; Stein et al., 2012). All of these factors have also been identified as variables that may contribute to PTSD symptom severity and treatment outcomes (Steenkamp et al., 2015). Additionally, active-duty service members remain in relatively dangerous situations during deployment, which places them at greater risk for repeated trauma exposure.

Discrepant findings on whether military populations benefit less from first-line PTSD psychotherapies may also be because, to our knowledge, previous meta-analyses have not separated military sexual trauma (MST) and combat-related trauma type in military populations. Research has found symptom presentation differences between MST victims and military populations with non-MST related PTSD (Carroll et al., 2018; Sexton et al., 2018). It is possible that MST is more akin to civilian sexual assault than to combat trauma, which in turn may impact treatment outcomes. Alternatively, it is possible that the impact of MST differs from that of civilian sexual assault, especially when perpetrated by a fellow service member with whom the victim may have continued contact and on whom the victim's continued safety may depend (e.g., in combat). Early research is mixed regarding treatment outcome differences between MST and non-sexual assault military traumas (Tiet, Leyva, Blau, & Turchik, 2015; Voelkel, Pukay-Martin, Walter, & Chard, 2015; Zalta et al., 2018). Therefore, separating military population studies by trauma type could provide an explanation for previous conflicting results regarding population and trauma type differences.

It is also important to consider that treatment outcome differences may not be impacted by the type of trauma, but rather characteristics that differ between military and civilian populations. For example, prior research has noted approximately 87% of treatment seeking military veterans with PTSD also meet criteria for at least one additional psychiatric comorbidity (Magruder et al., 2005). Military culture has also been identified as a factor that may interfere with optimal treatment response. Research has indicated that mental health stigma in the military may impact treatment seeking behavior and treatment dropout (Sharp et al., 2015). Mental health stigma beliefs may also result in treatment dropout and poor treatment attendance, which has been linked to worse PTSD treatment outcomes (Bush, Sheppard, Fantelli, Bell, & Reger, 2013; Tarrier, Sommerfield, Pilgrim, & Faragher, 2000). Military training is another factor that may interfere with treatment response by promoting hyperarousal PTSD symptoms, such as hypervigiliance and anger, as key strategies for survival (Yehuda, Vermetten, McFarlane, & Lehrner, 2014). It is also possible that other systemic factors, such as service connection disability claims and secondary gain, may

impede treatment gains (Guina, Welton, Broderick, Correll, & Peirson, 2016; McNally & Frueh, 2013). Although mental health stigma, cultural norms about the benefits of hypervigilance and avoidance, and disability claims are not entirely absent in civilian populations, they appear to be more prevalent in military populations.

The goal of this meta-analysis is to evaluate PTSD treatment outcomes as a function of trauma type and population. Specifically, we aim to evaluate whether military populations demonstrate a poorer treatment response from first-line PTSD psychotherapy interventions in comparison to civilians. Based on the existing evidence, we hypothesized that: (a) first-line treatments would result in treatment benefits across trauma types and population types; (b) combat traumas would yield smaller treatment benefits compared to other trauma types; and (c) military populations would report poorer treatment outcomes compared to civilian populations.

2. Methods

A systematic review of the literature was conducted to identify psychotherapy treatment outcome trials for PTSD from PsycINFO, PILOTS, and MEDLINE databases from January 1, 1980 to December 31, 2017. The rationale for selecting this start date was based on the formal introduction of PTSD as codified clinical diagnosis in the American Psychiatric Association Diagnostic and Statistical Manual, 3rd ed, which was published in 1980 (American Psychiatric Association, 1980). We used subject headings and keywords, when appropriate, for the following search terms, "(ptsd or post traumatic stress disorder or posttraumatic stress disorder or post-traumatic stress disorder) and (cognitive behavior* therapy or cbt or cognitive-behavio* therapy) or (cognitive processing therapy or CPT) or (prolonged exposure or prolonged exposure therapy or PE) or (eye movement desensitization and reprocessing or emdr) and (Adult*)." Additional inclusion criteria were that manuscripts were peer reviewed and published in English. Potential papers for inclusion were also identified through hand-searching published PTSD reviews, PTSD meta-analyses, and the references of retrieved articles.

2.1 Inclusion criteria

We included PTSD psychotherapy treatment outcome trials (controlled and uncontrolled studies) for adults with a diagnosis of PTSD. Studies that included participants with subthreshold PTSD were excluded from the meta-analysis. Selection of included intervention types was based on the International Society for Traumatic Stress Studies (ISTSS) PTSD treatment recommendation guidelines (ISTSS, 2018). Based on the ISTSS guidelines, we included studies that utilized at least one of four manualized, first-line psychotherapy treatments for PTSD: Prolonged Exposure (PE), Cognitive Processing Therapy (CPT), Eye Movement Desensitization and Reprocessing (EMDR), and Ehlers and Clark's (2005) Cognitive Therapy (CT) for PTSD.

The rationale to include only these four interventions was to mitigate treatment type confounds (e.g., first-line vs. non-first-line treatment options). Studies that utilized components of these interventions, implemented the interventions in a manner that was inconsistent with the standard protocol, or included an additive treatment component were

excluded from the meta-analysis. For example, if a study only used imaginal exposure, combined PE with another intervention, or implemented components of PE in a manner that was inconsistent with the protocol, that study was excluded. When a trial involved multiple condition arms and one of the arms was consistent with our inclusion criteria, we extracted the data for that condition alone and excluded the other treatment arms. For example, if a trial compared EMDR alone v. EMDR combined with medication, we extracted the data from the first condition and excluded the second condition.

Studies that utilized individual, face-to-face weekly or biweekly interventions in an outpatient setting were included in the meta-analysis. Although PTSD treatments using a group treatment modality, teletherapy/virtual options, daily (massed) delivery, and administration in a residential/inpatient setting have demonstrated positive treatment outcomes, these formats can include additional components that deviate from the initial protocol design or remain categorized as a non-first-line treatment option (ISTSS, 2018). For instance, residential PTSD treatments often include additional supplementary components (e.g., skills-based therapy, art therapy, etc.) that are not often utilized in conjunction with a first-line PTSD treatment delivered in an individual outpatient therapy format. We also excluded trials that focused on dual diagnosis treatment for PTSD and a comorbid issue because the primary focus of this meta-analysis was PTSD treatment outcomes alone. We did not exclude studies where participants endorsed a comorbid secondary condition as long as the aim of the study was PTSD treatment alone. Based on expert guidelines, studies with a protocol that was at least 4 sessions in length were eligible for inclusion (Foa et al., 2009).

Additional criteria for inclusion were that studies utilized an established PTSD outcome measure and an established PTSD diagnostic measure. The rationale for all of the listed exclusion decisions was to mitigate potential variables that may impact treatment outcomes and confound our primary analyses. When insufficient information was available to calculate an effect size, the primary study author was contacted to obtain the required information (i.e., Duffy, Gillespie, & Clark, 2007; Lee, Gavriel, Drummond, Richards, & Greenwald, 2002; Monson et al., 2006; Nacash et al., 2011; Popiel, Zawadzki, Pragiowska, & Teichman, 2015; Rauch et al., 2009; Schnurr et al., 2007; Thorp et al., 2012). Studies were excluded from analyses if the author could not be contacted or was unable to provide data. Based on the criteria outlined above, 28 studies were included. See Figure 1 for a flow chart of included studies.

2.2 Coding procedures and definitions

Outcome variables of interest were PTSD symptom severity mean scores at pre and posttreatment and the proportion of participants who no longer met criteria for PTSD at posttreatment. Additionally, study sample characteristics and study methodology was coded for each study to evaluated potential covariates that may predict treatment outcomes (see Table 1). Sample descriptive variables included percentage of participants that were female, mean participant age in years, and percentage of the sample who dropped out of treatment (attrition). Study methodology variables included intervention type (EMDR, CPT, PE, CT), PTSD treatment outcome/diagnostic measure used, method of PTSD measure administration (self-report v. clinical interview), statistical analysis method (intent to treat v. completer),

study year, and trial type (randomized clinical trial [RCT], clinical comparative trial [CCT], and uncontrolled clinical trial [UCT]). Intervention type coding included four categories of EMDR, CPT, PE, or CT. Coding for PTSD measures was based on the reported diagnostic and outcome-based measures used in the study. Effect sizes based on intent to treat were selected over effect sizes based on completers when both methods were reported in the study. For type of trial, there was one instance of a quasi-randomization that was coded as "Quasi" (i.e., Thorpe, Stein, Jeste, Patterson, & Loebach-Wethell, 2012). This study was excluded from the trial type covariate analysis

The first moderator variable of interest was trauma type. A minimum of three studies were required to establish a trauma type to maximize the number of identified trauma categories in the least restrictive manner. Based on this method, we defined and coded trauma type into three categories: a) combat, b) assault, or c) mixed. The combat trauma category was defined as a traumatic experience that occurred in the context of a combat-related event. The assault trauma category was defined as physical or sexual assault, and included one military sexual trauma study (i.e., Surís et al., 2013). The mixed trauma category included studies with various trauma types reported or a specific trauma type that did not have at least three studies to establish a specific trauma type subgroup. For example, Ehlers et al. (2014) included individuals with PTSD related to assault, accidents, disaster, and witnessing death. Alternatively, the sample in Capezzani et al. (2013) was composed of individuals with this trauma type. Based on the coding methods, both studies were assigned to the mixed category.

Four military population studies included participants with various trauma types (i.e., Nacash et al., 2011; Rauch et al., 2009; Schnurr et al., 2007; Thorp et al., 2012). For these studies, we contacted the primary author to request sub-sample effect size information for specific trauma types. Schnurr et al. was a military population sample that included participants with exposure to combat, assault (MST and non-military related assault), and other types of trauma types (e.g., accidents). Therefore, the Schnurr et al. study participants were separated into three groups for sub-group analyses by trauma type: combat (n = 7), assault (n = 74), and mixed (n = 30). Nacash et al. included a military population sample that included participants with exposure to combat (n = 10) and terror-related trauma types (n = 10)5). Participants with exposure to terror-related trauma were assigned to the mixed trauma category because this was the only study that included terror-related trauma. Studies by Rauch et al. (2009) and Thorp et al. (2012) also reported combat, assault, and mixed trauma type categories. However, only the combat trauma participants were included for these two studies because of small sample size (n < 3) in the other trauma categories (see Figure 3). Comprehensive Meta-Analysis will not calculate an effect size for samples this small. One military population study was not included in trauma type analyses, but was included in population analyses because the author could not be reached to provide information on trauma type (i.e., Monson et al., 2006).

The second moderator variable of interest was population type. Study population was coded as either military or civilian. A majority of the included military population studies were comprised of veterans and only one military study was made up of active-duty military

service members (i.e., Thorp et al., 2012). When a study sample was composed of military and civilian participants, we contacted the author to request sub-sample effect size information by population type (e.g., Lee et al., 2002).

2.3 Data analytic plan

In order to evaluate treatment outcome differences as a function of trauma type and population, we used random mixed-effects models with repeated measures, with time (prepost treatment) as the within group variable and trauma type or population type as the between group variable. Hedges' g was used as a measure of the weighted effect size for within group PTSD symptom severity outcomes (Hedges & Olkin, 1985). PTSD remission rate was also evaluated as a secondary outcome and as a measure of clinically meaningful improvement. PTSD remission was defined as the sample proportion that no longer met diagnostic criteria for PTSD at posttreatment as indicated by an evidence-based diagnostic instrument. Event rates analyses were used to evaluate PTSD remission rates at posttreatment in the total sample. Cochran's Q was utilized to test group differences in symptom severity and PTSD remission. When appropriate, post-hoc testing was performed using a partitioned chi-square analysis to evaluate groups of three or greater. The partitioned method allows for analysis of k-1 group comparisons that should sum to the total degrees of freedom in the omnibus chi-square. Informal interpretation of general difference across subgroup effect-size estimates were utilized to inform the specified contrast tests.

In this study, a positive effect size sign denotes symptom reduction scores from pretreatment to posttreatment. In instances where a study included multiple outcomes (e.g., PCL and CAPS) or multiple interventions (e.g., PE and CPT), a combined study effect size was calculated (e.g., Resick, Nishith, Weaver, Astin, & Feuer, 2002). Of note, a majority of studies did not report a pre-post score correlation coefficient which is a component of the repeated measures Hedges' *g* effect size formula. It is recommended to conduct a sensitivity analysis utilizing a range of plausible correlations when this occurs (Borenstein et al., 2009). However, Borenstein et al. (2009) do not provide specific sensitivity analysis estimates. Therefore, we used Cohen's (1988) recommended conventional interpretation of a small (. 10), medium (.30), and large (.50) correlation coefficients. This provided a range of plausible correlations with a varying degree of impact on pre-post change scores. Overall, findings based on these three correlation coefficients were not meaningfully different. Therefore, a medium pre-post score correlation (.30) was used across studies.

2.4 Preliminary analyses

Prior to evaluating the main hypotheses, we conducted outlier and publication bias analyses. We also evaluated treatment outcome differences across study methodology and descriptive factors to identify any variables that may impact treatment outcomes. We identified potential outlier studies utilizing the sample adjusted-meta-analytic deviance (SAMD) statistic (Huffcutt & Arthur, 1995). The SAMD statistic is based on the difference-in-fit standardized (DFFITS) statistic, which calculates a value approximate to a *t* distribution with and without that observation included. Values greater than 2.00 are considered large (Huffcutt & Arthur, 1995). However, we selected a cutoff of 2.25, which maximizes the ability to explore group differences (Beal, Corey, & Dunlap, 2000). If a study was identified as an outlier, this study

was removed from the primary model analyses. As the methods for the identification and management of outliers is not universally accepted, findings with potential outlier studies are also reported (Aguinis, Gottfredson, & Joo, 2013).

2.4.1 Publication bias analyses.—Fail-safe *N* analysis and trim and fill plot procedures were utilized to evaluate publication bias (Rosenthal, 1979; Duval & Tweedie, 2000). The fail-safe *N* calculates the robustness of significant meta-analytic findings by estimating the number of hypothesized missing studies required to nullify the summary effect. As the number of hypothesized missing studies required to result in null findings increases, there is less reason for concern regarding missing studies. The trim and fill approach estimates an adjusted effect size based on imputed estimates that result in a more symmetrical, unbiased funnel plot. Duval and Tweedie (2000) recommend this method as a sensitivity analysis with an emphasis on identifying how the effect size may change if missing studies exist.

2.4.2 Study and descriptive preliminary analyses.—A series of mixed-effects models and meta-regression analyses were also conducted prior to the main analyses to identify potential influential variables that may impact treatment outcomes and confound our primary aims. We evaluated differences between intervention type, PTSD measure used for diagnosis and outcome, method of PTSD measure administration, statistical analysis method, study year, trial type, gender, attrition, and publication year (see Table 1). When a study did not report specific descriptive information, that study was excluded from that analysis and the missing information was denoted with "NR = not reported" in Table 1. Multiple studies used self-report and clinician interview measures to assess PTSD. We evaluated outcome differences between these two methods prior to creating a combined composite score to rule out measure administration type confounds. We excluded one study (Resick et al., 2002) from the treatment type analysis because this study included both PE and CPT intervention arms.

2.4.3 Heterogeneity statistics.—Heterogeneity of the summary effect size was examined using the Cochran's Q statistic and P^2 index. The Q statistic is based on a chi square distrubution that tests if the observed distribution is significantly larger than expected as indicated by the within group error. As noted previously, the Q statistic can also be used to test group differences in subgroup analyses (Borenstein et al., 2009). Higgins and Thompson (2002) proposed the use of the P^2 statistic as a method of determing heterogeneity based on the ratio of true variance to total variance. P^2 can be understood as the percentage of between-studies variablitity in the effect esimates. Higgins and Thompson (2002) developed a classification system of P^2 values to interpret magnitude. $P^2 = 25\%$, $P^2 = 50\%$, and $P^2 = 75\%$ are classified as small, medium, and high cut-off benchmarks, respectively.

Analyses were conducted using Comprehensive Meta-Analysis. The SAMD estimates were calculated based on the recommended formulas (Huffcutt & Arthur, 1995). All studies were included in analyses unless otherwise specified in the text or indicated in tables and figures as missing or excluded.

3. Results

3.1 Total effect size analyses

Study characteristics are displayed in Table 1. The *n* across studies ranged from 8 to 141 and there was a total of 1,228 participants. Results yielded a large repeated measure total effect size across all studies, g = 1.44, SE = .09, p < .001. The total summary repeated measure effect size information is presented in Figure 2. Heterogeneity analyses of the summary effect with all included studies suggested there was not a common effect size across studies, and mixed effect subgroup analysis was warranted, Q(27) = 75.49, p < .001, $I^2 = 64.23$.

3.2 Preliminary analyses

Prior to examining trauma type and population, a series of outlier and publication bias analyses were conducted. We also ran a series of mixed-effects models to identify any methodological or descriptive study variables that may impact PTSD treatment outcomes.

3.2.1 SAMD statistic results.—SAMD outlier analyses are presented in Figure 2, and indicate one outlier study (Schnurr et al., 2007; SAMD = -2.97), which was therefore excluded from primary analyses. As exclusion of outliers is not a universally recommended method (Aguinis et al., 2013) and Schnurr et al. was a methodologically rigorous study, we also report outcomes with Schnurr et al. included in the model. Of note, heterogeneity statistics of the total summary effect with Schnurr et al. excluded from the model remained statistically significant (p < .001).

3.2.2 Fail-safe N and trim and fill analyses.—The fail-safe *N* analysis demonstrated that 5,251 missing studies with no effect of PTSD treatment were necessary to result in a non-significant *p* value. The funnel plot was slightly asymmetrical in favor of treatment effects. The trim-and fill analysis imputed seven studies opposed to the treatment effect (right) and zero studies in support of the treatment effect. Consideration of the imputed studies resulted in a small decrease ($g_{diff} = -0.13$) between the observed effect size (g = 1.44) and imputed effect size (g = 1.31).

3.2.3 Mixed-effects and meta-regression.—A series of preliminary analyses were conducted to evaluate treatment outcomes across descriptive and study methodology variables. Meta-regression analyses indicated that attrition rate was the only variable associated with treatment outcomes, B = -1.121, SE = .57, Z = -1.96, p = .05. Specifically, higher rates of attrition were related to worse treatment effects. All other study methodology and descriptive variables were found to be statistically null, p > .05.

3.3 Treatment outcomes as a function of trauma type and population

Two mixed-effects analyses were performed to evaluate PTSD treatment outcomes as a function of trauma type and population type (see Figures 3 & 4). A significant difference was found between trauma subgroups, Q(2) = 10.07, p = .006. The mixed subgroup demonstrated the largest effect size, g = 1.74, SE = 0.12, p < .001, followed by the assault trauma subgroup, g = 1.33, SE = 0.09, p < .001, and the combat trauma subgroup, g = 1.23, SE = 0.13 p < .001. Post-hoc analyses utilizing a partioned chi-square contrast method were

implemented to evaluate differences between groups. Because the mixed trauma group appeared to be different compared to the other two trauma type subgroups, we first evaluated differences between the mixed trauma subgroup and the combined assault and combat subgroups. The second contrast evaluated differences between the assault v. combat subgroups. Findings indicated that the treatment outcome effect in the mixed trauma subgroup was significantly larger than the combined assault/combat comparison, Q(1) = 9.71, p = .002. There was not a statistically significant difference in pre-post change scores between the assault and combat subgroups, Q(1) = 0.36, p = .56.

Population type analyses revealed significant differences in treatment outcomes between civilian and military populations, Q(1) = 6.19, p = .01. Specifically, the military population subgroup, g = 1.22, SE = .10, p < .001 demonstrated a smaller treatment response in comparison to the civilian subgroup, g = 1.55, SE = 0.08, p < .001.

Given that attrition rate was a significant predictor of treatment outcomes, we also evaluated whether there were population differences in attrition rates. Lee et al. (2002) was excluded from analyses as this study was comprised of military and civilians participants. The total sample across studies demonstrated an omnibus attrition rate of approximately 26%. Subgroup analysis indicated there was not a significant difference in attrition between populations, Q(1) = 0.28, p = .60. Both groups had a similar attrition rate, with the military subgroup, 28%, CI (0.21, 0.36), demonstrating a slightly higher rate of attrition compared to civilians, 25%, CI (0.20, 0.31). Trauma type differences in attrition rates were not conducted because attrition information was not available by trauma type for studies that were separated as described (see Section 2.2. Coding Procedures and Definitions).

3.4 PTSD remission rate as a measure of clinically meaningful change

Approximately 59% of participants across studies no longer met criteria for PTSD at posttreatment. Population subgroup analysis were also conducted to evaluate PTSD diagnostic remission differences between military and civilian subgroups. Lee et al. (2002) was excluded from this analyses because this study included military and civilian subgroups. Subgroup analysis indicated that military populations demonstrated poorer rates of PTSD remission at posttreatment compared to civilians, Q(1) = 4.39, p = .04. Specifically, 50%, CI (0.39, 0.62), of the military population subgroup no longer met criteria for PTSD at posttreatment, while 65%, CI (0.57, 0.72), of the civilian population subgroup no longer met criteria for PTSD at posttreatment.

3.5 Results with the outlier study included in models

All analyses were re-evaluated with the Schnurr et al. (2007) outlier study included in the model.¹ Preliminary analyses evaluating study and descriptive variables maintained similar patterns and significance levels with Schnurr et al. (2007) included in models. That is, attrition was the only variable that was predictive of treatment outcomes (p < .05). Treatment

¹All analyses were also evaluated with only the RCT studies included in the model (with and without the outlier study). Effect size statistics and the pattern of results were essentially unchanged ($g_{diff} = \pm 0.01$) in comparison to the results reported in text.

J Anxiety Disord. Author manuscript; available in PMC 2020 October 01.

outcomes did not vary by, nor were treatment outcome predicted by, any other study methodological or descriptive variable (p > .05).

When including the outlier study, trauma type no longer impacted treatment outcome, Q(2) = 3.24, p = .20. Specifically, the mixed trauma subgroup retained the largest effect size, but slightly decreased in magnitude compared to the first model, g = 1.64, SE = 0.18, p < .001; $g_{diff} = -0.10$. The combat trauma subgroup went from having the weakest effect in the first model to having the second largest effect in the second model, g = 1.30, SE = 0.20, p < .001; $g_{diff} = 0.07$. The assault trauma subgroup demonstrated the poorest treatment effect with the outlier study included in the model, g = 1.22, SE = 0.18, p < .001; $g_{diff} = -0.11$. In contrast, treatment outcome differences as a function of population remained significant when Schnurr et al. (2007) was included in the model, Q(1) = 9.14, p = .003. The civilian subgroup maintained a larger treatment effect size, g = 1.56, SE = 0.09, p < .001; $g_{diff} = 0.00$, compared to the military subgroup, g = 1.14, SE = 0.10, p < .001; $g_{diff} = -0.13$.

The pattern of PTSD remission rates was essentially unchanged when including the outlier study. That is, 57% of participants no longer met criteria for PTSD at posttreatment. Population differences in PTSD remission rates at posttreatment remained significant, Q(1) = 7.44, p = .006. With Schnurr et al. (2007) included in the model, 48%, CI (0.38, 0.58), of the military population subgroup no longer met criteria for PTSD, whereas 65%, CI (0.58, 0.72), of the civilian population subgroup no longer met criteria for PTSD at posttreatment.

4. Discussion

The primary aim of this meta-analysis was to evaluate PTSD treatment outcomes as a function of trauma type and population. Overall, there were large treatment effect sizes across studies and subgroups, indicating that first-line psychotherapy treatments for PTSD result in significant treatment benefits. Additionally, we evaluated PTSD remission rate as a measure of clinically meaningful change and, on average, 59% of the sample demonstrated PTSD remission at posttreatment. These findings provide additional support for the effectiveness of manualized, first-line psychotherapy treatments for PTSD that are strongly recommended among experts in the field (ISTSS, 2018).

Consistent with our second hypothesis, the combat subgroup benefitted less from treatment than did the mixed trauma subgroup. However, treatment response in the combat trauma subgroup was not different from the assault subgroup. These findings may be because the nature of assault and combat trauma events can be thought of as more severe compared to other trauma events, such as accidents, illness, and disasters. Additionally, assault and combat trauma events can be more chronic or repeated, although this is not always the case. Thus, these findings indicate that manualized, first-line PTSD psychotherapy treatments, although quite effective across trauma types, may be less effective in assault and combat trauma type categories relative to other trauma types.

This outcome is consistent with prior meta-analyses that have also found treatment outcomes variations as a function of trauma type (Bradley et al., 2005; Bisson et al., 2007; Sloan et al., 2013). Although Bradley et al. and Bisson et al. did not conduct specific subgroup test

comparisons, both meta-analyses reported smaller treatment effect sizes among combatrelated studies. Sloan et al (2013) carried out specific subgroup tests in a sample of groupbased PTSD interventions and found that the mixed trauma subgroup demonstrated the largest treatment effect size in comparison to other trauma subgroups, such as combatrelated trauma types. This meta-analysis extends this pattern of treatment outcome differences to individual treatments and incorporates assault trauma events.

Trauma type findings in this meta-analysis should be interpreted with consideration of how the outlier impacted results. Variations in trauma type results with the outlier study included v. excluded in the model can potentially be explained by two possibilities. First, the variability in trauma type findings may bring into question the relative importance of trauma type with regard to treatment outcomes. Prior meta-analyses have emphasized difficulties in disentangling trauma type as a factor that impacts treatment outcomes in military populations (Bisson et al., 2007; Bradley et al., 2005; Sloan et al., 2013; Watts et al., 2013). Differences in the statistical stability of trauma type v. population type when the outlier study was included in the model provides a possible indication that population may be a more influential variable.

A second possibility for variations in trauma type analysis with the outlier study included in the model is potentially related to the uniqueness of the Schnurr et al. (2007) study sample. The women in this sample reported varying trauma types including combat, assault, and mixed traumas. Across these three trauma types, women with assault appeared to have particularly poor outcomes (g = 0.26) compared to women with mixed (g = 0.82) and combat (g = 1.16) traumas. Military women in this study endorsed high levels of PTSD symptom severity and a high number of lifetime traumatic exposures ($M_{traumas} = 10$). It is likely that the comparatively smaller effect size (0.80), in this study reflects the high severity of trauma symptoms, the deleterious effects of a high rate of traumatic life events, the unique components of female military populations, and possibly the nature of MST.

Although there is some evidence to suggest that veterans who report MST as their index trauma have poorer PTSD treatment outcomes compared to veterans with combat-related index traumas (Zalta et al., 2018), unlike the Schnurr et al. (2007) subsample, those with MST-related index traumas still demonstrated large treatment effects in our meta-analysis (i.e., Surís et al., 2013). Moreover, there is also evidence indicating negligible difference in treatment outcomes for those with v. without MST (Tiet et al., 2015; Voelkel et al., 2015), which is similar to findings from this meta-analysis related to combat and assault-related traumas. Notably, all of these studies comparing those with MST v. combat trauma evaluated residential and intensive treatment programs. To our knowledge, there are no studies directly comparing treatment outcomes of weekly, first-line psychotherapy treatment for those with and without MST as their index trauma. Unfortunately, we were not able to examine MST as a separate trauma type category from assault in this meta-analysis. It is possible that the rudimentary trauma type categorization coding entirely masked the true effects of trauma type on treatment outcomes. Thus, the impact of trauma type on treatment outcomes warrants further evaluation and remains an empirical question. Future studies should explore how symptom presentation differences between combat-related PTSD and MST impact treatment outcomes.

The military population subgroup demonstrated a poorer treatment response compared to civilians as indicated by effect size differences and PTSD remission rates at posttreatment. This is consistent with our hypothesis and in line with prior meta-analytic results that have highlighted that military populations do not benefit from PTSD psychotherapy treatment to the same degree as civilians (Bisson et al., 2007; Bradley et al., 2005; Sloan et al., 2013; Steenkamp et al., 2015; Watts et al., 2013). Individual factors (e.g., psychiatric comorbidities) and systemic factors (e.g., mental health stigma and secondary gain) have been identified as important variables for consideration with regard to treatment engagement and outcomes in military populations (Bush et al., 2013; Guina et al., 2016; Magruder et al., 2005; McNally & Frueh, 2013 Tarrier et al., 2000). Although prior research has highlighted the importance of considering these factors in psychotherapy treatment, minimal research has evaluated these issues. Therefore, the direct influence of these variables on treatment outcomes remains an empirical question.

Although pre-post treatment effects were large for all trauma and population types, across all groups, more than 40% of individuals continued to meet criteria for PTSD at posttreatment. This was even greater among military populations, half of whom still had PTSD after treatment. These findings are generally consistent with prior literature (Steenkamp et al., 2015), and highlight the dire need to develop ways to improve treatment outcomes even though existing treatments yield large improvements on average. Further, this meta-analysis extends previous PTSD remission rate findings by directly comparing differences between military and civilian populations PTSD remission rates.

Higher rate of attrition was predictive of poorer treatment gains based on exploratory analyses, which is consistent with previous meta-analytic findings (Bradley et al., 2005; Sloan et al., 2013). Factors related to attrition may be different in civilian and military samples. For example, military culture factors, such as mental health stigma and career impact, could affect treatment seeking and attrition in military populations (Bush et al., 2013; Sharp et al., 2015). However, there was not a significant difference in attrition rates between civilians and military subgroups. An absence of attrition rate differences supported previous research showing that attrition rates with first-line psychotherapy treatments for PTSD are a concern across populations (Garcia, Kelley, Rentz, & Lee, 2011; Imel, Laska, Jakcupcak, & Simpson, 2013; Steenkamp et al., 2015). Nonetheless, it is imperative that future research identify and be mindful of specific cultural factors that may lead to attrition across military and civilian populations.

We found no differences in treatment outcomes as a function of gender or age. The absence of gender effects in this study differs from previous PTSD treatment outcome reviews that suggest women experience greater symptom reductions than men (Wade et al., 2016; Watts et al., 2013). This discrepancy with previous research may potentially be explained by our decision to include only manualized, first-line psychotherapy treatments whereas previous meta-analyses included a more liberal criteria. The null findings for age effects were consistent with previous research demonstrating the effectiveness of PTSD treatment across age groups (Clapp & Beck, 2012; Cook, McCarthy, & Thorp, 2017). Taken together, findings from this meta-analysis provide additional support that first-line psychotherapy treatments for PTSD are effective regardless of age or gender.

A final point for discussion is consideration of publication bias. Fail-safe *N* analyses revealed minimal concerns for publication bias based on the number of studies required to produce a null effect, whereas trim and fill analysis found a slightly asymmetrical funnel plot suggestive of minor publication bias. Although trim and fill analysis produced a slightly asymmetrical funnel plot, the difference between the imputed effect size and the observed effect size was relatively trivial. Additionally, an asymmetrical funnel plot can indicate publication bias, but asymmetry may also be due to different causes other than publication bias, such as heterogeneity (Egger, Davey-Smith, Schneider, & Minder, 1997; Sterne, Egger, & Davey-Smith, 2001). Therefore, the presence of heterogeneity in this meta-analysis is a plausible explanation for the asymmetrical funnel plot. While publication bias was present to a degree in this study, and is an important consideration across meta-analyses, the presence of symmetry and small effect size difference between observed and imputed estimates provides an increased degree of confidence in findings from this meta-analysis.

4.1 Limitations

Several limitations should be noted from this review. First, there were a limited number of trials that utilized a first-line, manualized psychotherapy treatment for PTSD and provided information on specific trauma types that yielded effect size data. Review of the literature suggested that specific trauma type information was not consistently provided across trials and typically only a brief description of trauma type was provided, with insufficient information to parse apart trauma type by outcome effects. This trend was present across trauma types included in this study and resulted in utilizing broad categories (e.g., Mixed) to develop an adequate number of trauma type subgroups. The use of broad, generalized trauma categories may have masked treatment outcomes effects by trauma type and may also explain variations in trauma type findings discussed above. Additionally, there were challenges in defining trauma type in military-related studies. A number of studies utilized the term *military-related trauma* which was representative of a variety of trauma types, such as MST, combat trauma, training accidents, and in some cases traumas that may have occurred outside of the military. We directly contacted authors to parse apart trauma differences in military studies. However, there were limitations in data availability, which in turn resulted in a slightly rudimentary categorization of study samples. Additionally, individuals were categorized into specific trauma groups based on their presenting trauma event (i.e., index event); however, it is likely many individuals across studies had experienced multiple traumas in their lifetime that were representative of different trauma categories. All these factors may have impacted trauma type results and findings should be interpreted within the context of these limitations. This meta-analysis highlights the challenges of evaluating trauma type based on how this information is reported in the literature. The question as to whether treatment outcomes vary as a function of trauma type requires further investigation.

Another limitation is that we were unable to evaluate potential differences between activeduty military and veteran populations because the military sample in this meta-analysis was almost entirely composed of veterans. We were also unable to evaluate various systemic and individual factors that may impact psychological treatment among active-duty military service members v. veterans. Indeed, previous research has identified individual and

systemic differences between active-duty and veteran populations, such as stigma, career threat, avoidance of deployment, and secondary gain (Guina et al., 2016; McNally & Frueh, 2013). These factors may result in symptom minimization or exaggeration, influence motivation to seek or to benefit from treatment, and may vary across active-duty and veteran populations. Future research should evaluate such potential differences between active-duty military and veteran populations.

A final limitation to note is the generalizability of findings to alternative treatment types, treatment modalities, and treatment settings that were excluded from this meta-analysis, such as teletherapy, group therapy, and residential treatment settings. Our rationale to include only select interventions was to mitigate confounding variables and focus exclusively on *highly recommended* PTSD treatments. Although such interventions were excluded from this study, these methods have displayed positive evidence for military populations (e.g., Zalta et al., 2018). Findings should be interpreted within the context of the included treatment types, treatment modalities, and treatment settings. Moreover, future research should explore whether alternative methods of treatment delivery can help to improve treatment response for military populations.

4.2 Conclusions

Overall, first-line, manualized psychotherapies for PTSD appear to be very effective in ameliorating symptoms of PTSD across populations and trauma types. Despite the effectiveness of these treatments, military populations demonstrated worse treatment outcomes compared to civilians, and these differences appear to be robust. In contrast, specific trauma types that may be more severe in nature (e.g., assault and combat) were associated with poorer treatment response compared to other trauma types. Trauma type appeared to be a less robust finding and the inclusion of one outlier study resulted in trauma type differences becoming non-significant. Hence, the impact of trauma type warrants further investigation. Finally, a large minority of individuals across all groups did not achieve remission, and this number was particularly large in the military group. Together, these data highlight the necessity of continued efforts to improve treatment outcomes.

Declarations of Interest:

Alyson Zalta is supported by a career development award from the National Institute of Mental Health (K23 MH103394). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Submission Declaration: This manuscript has not been published previously and is not under consideration for publication elsewhere. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References²

- Aguinis H, Gottfredson RK, & Joo H (2013). Best-practice recommendations for defining, identifying, and handling outliers. Organizational Research Methods, 16, 270–301.
- American Psychological Association (APA). (2017). Clinical practice guidelines for the treatment of PTSD in adults. Retrieved from: https://www.apa.org/ptsd-guideline/index

²References marked with an asterisk denote studies included in the meta-analysis.

JAnxiety Disord. Author manuscript; available in PMC 2020 October 01.

- American Psychiatric Association. (1980). Diagnostic and statistical manual of mental disorders (3rd ed.). Washington, DC: American Psychiatric Association.
- *. Asukai N, Saito A, Tsuruta N, Kishimoto J, Nishikawa T (2010). Efficacy of exposure therapy for Japanese patients with posttraumatic stress disorder due to mixed traumatic events: A randomized controlled study. Journal of Traumatic Stress, 23, 744–50. [PubMed: 21171135]
- Beal DJ, Corey DM, & Dunlap WP (2002). On the bias of Huffcutt and Arthur's (1995) procedure for identifying outliers in the meta-analysis of correlations. The Journal of Applied Psychology, 87(3), 583–89. [PubMed: 12090616]
- Bisson J, Ehlers A, Matthews R, Piling S, Richards D, & Turner S (2007). Psychological treatments for chronic post-traumatic stress disorder: Systematic review and meta-analysis. The British Journal of Psychiatry, 190, 97–104. [PubMed: 17267924]
- Borenstein M, Hedges LV, Higgins JP, & Rothstein HR (2009). Introduction to meta-analysis. Hoboken, NJ: Wiley.
- Bradley R, Greene J, Russ E, Dutra L, & Westen D (2005). A multidimensional meta-analysis of psychotherapy for PTSD. The American Journal of Psychiatry, 162, 214–27. [PubMed: 15677582]
- Bush NE, Sheppard SC, Fantelli E, Bell KR, & Reger MA (2013). Recruitment and attrition issues in military clinical trials and health research studies. Military Medicine, 178, 1157–63. [PubMed: 24183761]
- *. Capezzani L, Ostacoli L, Cavallo M, Carletto S, Fernandez I, Solomon R, ... & Cantelmi T (2013). EMDR and CBT for cancer patients: Comparative study of effects on PTSD, anxiety, and depression. Journal of EMDR Practice and Research, 7, 134–43.
- *. Carlson JG, Chemtob CM, Rusnak K, Hedlund NL, & Muraoka MY (1998). Eye movement desensitization and reprocessing (EMDR) treatment for combat-related posttraumatic stress disorder. Journal of Traumatic Stress, 11, 3–24. [PubMed: 9479673]
- Carroll KK, Lofengren AM, Weaver DC, Held P, Klassen BJ, Smith DL, ... & Zalta AK (2018). Negative posttraumatic cognitions among military sexual trauma survivors. Journal of Affective Disorders, 238, 88–93. [PubMed: 29864715]
- *. Chard K, Schumm JA, Owens GP, & Cottingham SM (2010). A comparison of OEF and OIF and Vietnam veterans receiving outpatient cognitive processing therapy. Journal of Traumatic Stress, 23, 25–32. [PubMed: 20146255]
- Clapp JD, & Beck JG (2012). Treatment of PTSD in older adults: Do cognitive-behavioral interventions remain viable? Cognitive and Behavioral Practice, 19, 126–35. [PubMed: 22383863]
- Cohen J (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Earlbaum Associates.
- Cook JM, McCarthy E, & Thorp SR (2017). Older adults with PTSD: Brief state of research and evidence-based psychotherapy case illustration. American Journal of Geriatric Psychiatry, 25, 522–30. [PubMed: 28214073]
- Cusack K, Jonas DE, Forneris CA, Wines C, Sonis J, Cook-Middleton J, ... & Gaynes BN (2016). Psychological treatments for adults with posttraumatic stress disorder: A systematic review and meta-analysis. Clinical Psychology Review, 43, 128–41. [PubMed: 26574151]
- *. Devilly GJ, & Spence SH (1999). The relative efficacy and treatment distress of EMDR and a cognitive-behavior trauma treatment protocol in the amelioration of posttraumatic stress disorder. Journal of Anxiety Disorders, 13, 131–57. [PubMed: 10225505]
- Duffy M, Gillespie K, Clark DM (2007). Post-traumatic stress disorder in the context of terrorism and other civil conflict in Northern Ireland: Randomised controlled trial. British Medical Journal, 334, 1147–54. [PubMed: 17495988]
- Duval S, & Tweedie R (2000). Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics, 56, 455–63. [PubMed: 10877304]
- Egger M, Davey-Smith G, Schneider M, & Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal, 315, 629–634. [PubMed: 9310563]
- *. Ehlers A, Clark DM, Hackman A, McManus F, & Fennell M (2005). Cognitive therapy for posttraumatic stress disorder: Development and evaluation. Behaviour Research and Therapy, 43, 413–31. [PubMed: 15701354]


- *. Ehlers A, Hackman A, Grey N, Wild J, Liness S, Albert I, ... & Clark DM (2014). A randomized controlled trial of 7-day intensive and standard weekly cognitive therapy for PTSD and emotionfocused supportive therapy. The American Journal of Psychiatry, 171, 294–304. [PubMed: 24480899]
- *. Feske U (2008). Treating low-income and minority women with posttraumatic stress disorder: A pilot study comparing prolonged exposure and treatment as usual conducted by community therapists. Journal of Interpersonal Violence, 23, 1027–40. [PubMed: 18292398]
- *. Foa EB, Dancu CV, Hembree EA, Jaycox LH, Meadows EA, & Street GP (1999). A comparison of exposure therapy, stress inoculation training, and their combination for reducing posttraumatic stress disorder in female assault victims. Journal of Consulting and Clinical Psychology, 67(5), 194–200. [PubMed: 10224729]
- *. Foa EB, Hembree EA, Cahill SP, Rauch SA, Riggs DS, Feeny NC, & Yadin E (2005). Journal of Consulting and Clinical Psychology, 73(5), 953–64. [PubMed: 16287395]
- Foa EB, Keane TM, Friedman MJ, & Cohen JA (Eds.). (2009). Effective treatments for PTSD (2n ed.). New York, NY: Guilford Press.
- *. Foa EB, Rothbaum BO, Riggs DS, & Murdock TB (1991). Treatment of posttraumatic stress disorder in rape victims: A comparison between cognitive-behavioral procedures and counseling. Journal of Consulting and Clinical Psychology, 59(5), 715–23. [PubMed: 1955605]
- *. Forbes D, Lloyd D, Nixon RD, Elliott P, Varker T, Perry D, ... & Creamer M (2012). A multisite randomized controlled effectiveness trial of cognitive processing therapy for military-related posttraumatic stress disorder. Journal of Anxiety Disorder, 26, 442–52.
- *. Galovski TE, Blain LM, Mott JM, Elwood L, & Houle T (2012). Manualized therapy for PTSD: Flexing the structure of cognitive processing therapy. Journal of Consulting and Clinical Psychology, 80, 968–81. [PubMed: 23106761]
- Garcia HA, Kelley LP, Rentz TO, & Lee S (2011). Pretreatment predictors of dropout from cognitive behavioral therapy for PTSD in Iraq and Afghanistan war veterans. Psychological Services, 8, 1–11.
- Goodson J, Helstrom A, Halpern J, Ferenschack MP, Gillihan SJ, & Powers MB (2011). Treatment of posttraumatic stress disorder in U.S. Combat veterans: A meta-analytic review. Psychological Reports, 109, 573–99. [PubMed: 22238857]
- Green JD, Bovin MJ, Erb SE, Lachowicz M, Gorman KR, Rosen RC, ... & Marx BP (2015). The effect of enemy combat tactics on PTSD prevalence rates: A comparison of Operation Iraqi Freedom deployment phases in a sample of male and female veterans. Psychological Trauma Theory, Research, Practice, and Policy, 8, 634–40.
- Guina J, Welton RS, Broderick PJ, Correll TL, & Peirson RP (2016). DSM-5 criteria and its implication for diagnosing PTSD and military service members and veterans. Current Psychiatry Reports, 18, 43. [PubMed: 26971499]
- Hedges LV, & Olkin I (1985). Statistical methods for meta-analysis. Orlando, FL: Academic Press.
- Higgins JP, & Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Statistics in Medicine, 21, 1539–58. [PubMed: 12111919]
- *. Högberg G, Pagani M, Örjan S, Soares J, Åberg-Wistedt, Tärnell B, & Hällström T (2007). On treatment with eye movement desensitization and reprocessing of chronic post-traumatic stress disorder in public transportation workers: A randomized controlled trial. Nordic Journal of Psychiatry, 61, 54–61. [PubMed: 17365790]
- Hoge CW, Terhakopian A, Castro CA, Messer SC, & Engel CC (2007). Association of posttraumatic stress disorder with somatic symptoms, health care visits, and absenteeism among Iraq War Veterans. The American Journal of Psychiatry, 164, 150–53. [PubMed: 17202557]
- Huffcutt AI, & Arthur W (1995). Development of a new outlier statistic for meta-analytic data. The Journal of Applied Psychology, 80, 327–334.
- Imel ZE, Laska K, Jakcupcak M, & Simpson T (2013). Meta-analysis of dropout in treatments for posttraumatic stress disorder. Journal of Consulting and Clinical Psychology, 81, 394–404. [PubMed: 23339535]
- Institute of Medicine (IOM). 2008 Treatment of posttraumatic stress disorder: An assessment of the evidence. Washington, DC: The National Academies Press.

- International Society for Traumatic Stress Studies (ISTSS). 2018 Posttraumatic stress disorder prevention and treatment guidelines: Methodology and recommendations. Retrieved from: http://www.istss.org/treating-trauma/new-istss-prevention-and-treatment-guidelines.aspx
- Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, & Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62, 593–602. [PubMed: 15939837]
- Kline AC, Cooper AA, Rytwinksi NK, & Feeny NC (2018). Long-term efficacy of psychotherapy for posttraumatic stress disorder: A meta-analysis of randomized controlled trials. Clinical Psychology Review, 59, 30–40. [PubMed: 29169664]
- Kok BC, Herrell RK, Thomas JL, & Hoge CW (2012). Posttraumatic stress disorder associated with combat service in Iraq or Afghanistan: Reconciling prevalence differences between studies. The Journal of Nervous and Mental Disease, 200, 444–50. [PubMed: 22551799]
- *. Lee C, Gavriel H, Drummond P, Richards J, & Greenwald R (2002). Treatment of ptsd: Stress inoculation training with prolonged exposure compared to EMDR. Journal of Clinical Psychology, 58, 1071–89. [PubMed: 12209866]
- Litz B, Stein N, Delaney E, Lebowitz L, Nash WP, Silva C, & Maguen S (2009). Moral injury and moral repair in war veterans: A preliminary model and intervention strategy. Clinical Psychology Review, 29, 695–06. [PubMed: 19683376]
- Magruder KM, Frueh BC, Knapp RG, Davis L, Hamner MB, Martin RH, ... Arana GW (2005). Prevalence of posttraumatic stress disorder in Veterans Affairs primary care clinics. General Hospital Psychiatry, 27, 169–79. [PubMed: 15882763]
- McNally RJ, & Frueh BC (2013). Why are Iraq and Afghanistan War veterans seeking PTSD disability compensation at unprecedented rates? Journal of Anxiety Disorder, 27, 520–26.
- *. Monson CM, Schnurr PP, Resick PA, Friedman MJ, YoungXu Y, & Stevens SP (2006). Cognitive processing therapy for veterans with military-related posttraumatic stress disorder. Journal of *Consulting and Clinical Psychology*, 74, 898–907. [PubMed: 17032094]
- *. Nacash N, Foa EB, Huppert JD, Tzur D, Fostick L, Dinstein Y, ... & Zohar J (2011). Prolonged exposure therapy for combat- and terror-related posttraumatic stress disorder: A randomized control comparison with treatment as usual. The Journal of Clinical Psychiatry, 72, 1174–80. [PubMed: 21208581]
- *. Nijdam MJ, Gersons BPR, Reitsma JB, de Jongh A, & Olff M (2012). Brief eclectic psychotherapy v. Eye movement desensitisation and reprocessing therapy for post-traumatic stress disorder: Randomised controlled trial. The British Journal of Psychiatry, 200, 224–31. [PubMed: 22322458]
- *. Power K, McGoldrick T, Brown K, Buchanan R, Sharp D, Swanson V, & Karatzias A (2002). A controlled comparison of eye movement desensitization and reprocessing versu exposure plus cognitive restructuring versus waiting list in the treatment of post-traumatic stress disorder. Clinical Psychology and Psychotherapy, 9, 299–318.
- *. Popiel A, Zawadzki B, Pragiowska E, & Teichman Y (2015). Prolonged exposure, paroxetine, and the combination in the treatment of PTSD following a motor vehicle accident. A randomized clinical trial – The "TRAKT" study. Journal of Behavior Therapy and Experimental Psychiatry, 48, 17–26. [PubMed: 25677254]
- Powers MB, Halpern JM, Ferenshak MP, Gilliahn SJ, & Foa EB (2010). A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clinical Psychology Review, 30, 635–41. [PubMed: 20546985]
- *. Rauch SAM, Defever E, Favorite T, Duroe A, Garrity C, Martis B, & Liberzon (2009). Prolonged exposure for PTSD in a veterans health administration PTSD clinic. Journal of Traumatic Stress, 22, 60–64. [PubMed: 19145643]
- *. Rauch SAM, King AP, Abelson J, Tuerk PW, Smith E, Rothbaum BO, ... & Liberzon I (2015). Biological and symptom changes in posttraumatic stress disorder treatment: A randomized clinical trial. Depression and Anxiety, 32, 204–12. [PubMed: 25639570]
- *. Resick PA, Galovski TE, Uhlmansiek MO, Scher CD, Clum GA, & Young-Xu Y (2008). A randomized clinical trial to dismantle components of cognitive processing therapy for

posttraumatic stress disorder in female victims of interpersonal violence. Journal of Consulting and Clinical Psychology, 76, 243–58. [PubMed: 18377121]

- *. Resick PA, Nishith P, Weaver TL, Astin MC, & Feuer CA (2002). A comparison of cognitiveprocessing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims. Journal of Consulting and Clinical Psychology, 70, 867–79. [PubMed: 12182270]
- Rosenthal R (1979). The 'file drawer problem' and tolerance for null results. Psychological Bulletin, 86, 638–41.
- *. Schnurr PP, Friedman MJ, Engel CC, Foa EB, Shea MT, Chow BK, ... & Bernardy N (2007). Cognitive behavioral therapy for posttraumatic stress disorder in women: A randomized controlled trial. Journal of the American Medical Association, 297, 820–30. [PubMed: 17327524]
- Sexton MB, Davis MT, Bennett DC, Morris DH, & Rauch SAM (2018). A psychometric evaluation of the Posttraumatic Cognitions Inventory with Veterans seeking treatment following military trauma exposure. Journal of Affective Disorder, 226, 232–38.
- Sharp M, Fear NT, Rona RJ, Wessely S, Greenburg N, Jones N, & Goodwin L (2015). Stigma as a barrier to seeking health care among military personnel with mental health problems. Epidemilogic Reviews, 37, 144–62.
- Sifferlin A (2015, 8). How effective are PTSD treatments for veterans? Retrieved from: http://time.com/3982440/ptsd-veterans/
- Sloan DM, Feinstein BA, Gallagher MW, Beck JG, & Keane TM (2013). Efficacy of group treatment for posttraumatic stress symptoms: A meta-analysis. Psychological Trauma Theory, Research, Practice, and Policy, 5, 176–83.
- Steenkamp MM, Litz BT, Hoge CW, & Marmar CR (2015). Psychotherapy for military-related PTSD: A review of randomized clinical trials. Journal of the American Medical Association, 314, 489– 500. [PubMed: 26241600]
- Stein NR, Mills MA, Arditte K, Mendoza C, Borah AM, Resick PA, Litz BT, & the STRONG STAR Consortium. (2012). A scheme for categorizing traumatic military events. Behavior Modification, 36, 785–805.
- Sterne JA, Egger M, & Davey-Smith G (2001). Investigating and dealing with publication and other biases in meta-analysis. British Medical Journal, 323, 101–105. [PubMed: 11451790]
- *. Surís A, Link-Malcolm J, Chard K, Ahn C, & North C (2013). A randomized clinical trial of cognitive processing therapy for veterans with PTSD related to military sexual trauma. Journal of Traumatic Stress, 26, 28–37. [PubMed: 23325750]
- Taft CT, Watkins LE, Stafford J, Street AE, & Monson CM (2011). Posttraumatic stress disorder and intimate relationship problems: A meta-analysis. Journal of Consulting and Clinical Psychology, 79, 22–33. [PubMed: 21261431]
- Tarrier N, Sommerfield C, Pilgrim H, & Faragher B (2000). Factors associated with outcome of cognitive–behavioural treatment of chronic post-traumatic stress disorder. Behaviour Research and Therapy, 38, 191–202. [PubMed: 10661003]
- Thomas JL, Wilk JE, Riviere LA, McGurk D, Castro CA, & Hoge CW (2010). Prevalence of mental health problems and functional impairment among active component and National Guard soldiers 3 and 12 months following combat in Iraq. Archives of General Psychiatry, 67, 614–23. [PubMed: 20530011]
- *. Thorp SR, Stein MB, Jeste DV, Patterson TL, & Wetherell JL (2012). Prolonged exposure therapy for older veterans with posttraumatic stress disorder: A pilot study, American Journal of Geriatric Psychiatry, 20(3), 276–80. [PubMed: 22273763]
- Tiet QQ, Leyva YE, Blau K, Turchik JA, & Rosen CS (2015). Military sexual assault, gender, and PTSD treatment outcomes of US Veterans. Journal of Traumatic Stress, 28, 92–101. [PubMed: 25847514]
- *. Tuerk PW, Yoder M, Grubaugh A, Myrick H, Hamner M, & Acierno R (2011). Prolonged exposure therapy for combat-related posttraumatic stress disorder: An examination of treatment effectiveness for veterans of the wars in Afghanistan and Iraq. Journal of Anxiety Disorders, 25, 397–403. [PubMed: 21131170]

- U.S. Department of Veterans Affairs, Department of Defense. VA/DOD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder The Management of Posttraumatic Stress Disorder Work Group with support from The Office of Quality, Safety and Value, VA, Washington, DC & Office of Evidence Based Practice, U.S. Army Medical Command; Version 3.0 – 2017.
- Voelkel E, Pukay-Martin ND, Walter KH, & Chard KM (2015). Effectiveness of cognitive processing therapy for male and female US veterans with and without military sexual trauma. Journal of Traumatic Stress, 28, 174–82. [PubMed: 25976767]
- Wade D, Varker T, Kartal D, Hetrick S, O'Donnell M, & Forbes D (2016). Gender difference in outcomes following trauma-focused interventions for posttraumatic stress disorder: Systematic review and meta-analysis. Psychological Trauma Theory, Research, Practice, and Policy, 8, 356– 64.
- Watts BV, Schnurr PP, Mayo L, Young-Xu Y, Weeks WB, & Friedman MJ (2013). Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. The Journal of Clinical Psychiatry, 74, 541–50.
- Yehuda R, Vermetten E, McFarlane AC, & Lehrner A (2014). PTSD in the military: Special considerations for understanding prevalence, pathophysiology and treatment following deployment. European Journal of Psychotraumatology, 5, 1–7.
- Zalta AK, Held P, Smith DL, Klassen BJ, Lofgreen AM, Normand PS, ... & Karnik NS (2018). Evaluating patterns and predictors of symptom change during a three-week intensive outpatient treatment for veterans with PTSD. BMC Psychiatry, 18, 242. [PubMed: 30053860]





Study Name	g	SE	р	SAMD		Hedge	s' g & 95% (CI	
Asukai et al. 2010	1.68	0.52	.001	0.45		1	I —		1
Capezzani et al. 2013	1.87	0.42	.000	1.01			· · ·	_	
Carlson et al. 1998	1.07	0.45	.017	-0.39				⊢ −	
Chard et al. 2010	1.29	0.16	.000	-0.37			- I - I	∎-	
Devilly and Spence 1999	1.05	0.45	.021	-0.45				⊢ –I	
Ehlers et al. 2005	2.24	0.59	.000	1.39			- I -	 =	·
Ehlers et al. 2014	2.11	0.38	.000	1.84					
Feske 2008	1.42	0.53	.008	0.05			I —	▰┼╴	
Foa et al. 1991	1.05	0.44	.017	-0.42				⊢	
Foa et al. 1999	1.95	0.42	.000	1.22				+	
Foa et al. 2005	1.36	0.18	.000	-0.06				╉╌│	
Forbes et al. 2012	1.11	0.27	.000	-0.65			_ _∎	⊢∣	
Galovski et al. 2012	1.71	0.25	.000	1.11				∎-	
Hogberg et al. 2007	0.87	0.38	.023	-0.73				- 1	
Lee et al. 2002	1.89	0.56	.001	0.76			-	-	
Monson et al. 2006	1.40	0.30	.000	0.06			I –	▰┤	
Nacash et al. 2010	2.33	0.58	.000	1.60					-
Nijdam et al. 2012	1.83	0.23	.000	1.72					
Popiel et al. 2015	1.73	0.17	.000	1.67					
Power et al. 2002	2.30	0.51	.000	1.87					
Rauch et al. 2009	2.00	0.63	.002	0.82			- I -		
Rauch et al. 2015	2.87	0.79	.000	2.07				_┼╼	->
Resick et al. 2002	1.26	0.14	.000	-0.54			1 1		
Resick et al. 2008	1.42	0.17	.000	0.23			<u> </u>	▰┤	
Schnurr et al. 2007*	0.80	0.10	.000	-2.97				.	
Suirs et al. 2013	1.00	0.14	.000	-1.18				<u>-</u>	
Thorp et al. 2012	1.36	0.55	.013	-0.01					
Tuerk et al. 2011	1.04	0.18	.000	-1.19					
Total Random ES	1.44	0.09	.000			I	1	₹ 1	1
					-4.00	-2.00	0	2.00	4.00

Figure 2.

Repeated Measures Treatment Effect Sizes with SAMD. N = 1,228; g = Hedges' g; SE = Standard Error; SAMD = sample adjusted-meta-analytic deviance; ES = effect size. *The study was identified as an outlier based n the SAMD statistic > 2.25. The total random effect size increased, g = 1.46, SE = .08, p < .001, with the outlier study (Schnurr et al., 2007) removed from the model.

4.00

ske 2008 1.42 0.53 .008 a et al. 1991 1.05 0.44 .017 a et al. 1999 1.95 0.42 .000 a et al. 2005 1.36 0.18 .000 lovski et al. 2012 1.71 0.25 .000 sick et al. 2002 1.26 0.14 .000 sick et al. 2008 1.42 0.17 .000 sick et al. 2013 1.00 0.14 .000 ssault ES 1.33 0.10 .000 rlson et al. 1998 1.07 0.45 .017 ard et al. 2010 1.29 0.16 .000 rbs et al. 2012 1.11 0.27 .000 cash et al. 2012 1.45 0.57 .011 uch et al. 2011 1.04 0.18 .000 ompt ES 1.23 0.12 .000 ukai et al. 2010 1.68 0.52 .001 ucash et al. 2014 2.11 0.38 .000 willy and Spence 1999 1.05 0.45 .021 lers et al. 2007 0.87	Study Name	g	SE	р	Hedg	ges' g & 95%
a et al. 1991 1.05 0.44 .017 a et al. 1999 1.95 0.42 .000 a et al. 2005 1.36 0.18 .000 lovski et al. 2012 1.71 0.25 .000 sick et al. 2002 1.26 0.14 .000 sick et al. 2008 1.42 0.17 .000 irs et al. 2013 1.00 0.14 .000 ssault ES 1.33 0.10 .000 rlson et al. 1998 1.07 0.45 .017 ard et al. 2010 1.29 0.16 .000 rbes et al. 2012 1.11 0.27 .000 cash et al. 2012 1.11 0.27 .000 cash et al. 2011-1 2.14 0.66 .001 uch 2009 1.04 0.48 .031 uch et al. 2015 2.87 0.79 .000 orp et al. 2012 1.45 0.57 .011 erk et al. 2011 1.04 0.18 .000 ombat ES 1.23 0.12 .000 ukai et al. 2010 1.68 0.52 .001 pezzani et al. 2013 1.87 0.42 .000 willy and Spence 1999 1.05 0.45 .021 lers et al. 2014 2.11 0.38 .000 ogberg et al. 2007 0.87 0.38 .023 e et al. 2007 1.89 0.56 .001 cash et al. 2012 1.83 0.23 .000 piel et al. 2015 1.73 0.17 .000 wer et al. 2002 2.30 0.51 .000	Feske 2008				1	I —
a et al. 1999 a et al. 2005 a et al. 2005 blovski et al. 2012 cloveski et al. 2002 bloveski et al. 2002 cloveski et al. 2002 cloveski et al. 2008 cloveski et al. 2008 cloveski et al. 2008 cloveski et al. 2008 cloveski et al. 2013 cloveski et al. 2013 cloveski et al. 2013 cloveski et al. 2013 cloveski et al. 2010 cloveski et al. 2010 cloveski et al. 2010 cloveski et al. 2012 cloveski et al. 2012 cloveski et al. 2012 cloveski et al. 2012 cloveski et al. 2011 cloveski et al. 2013 cloveski et al. 2013 cloveski et al. 2013 cloveski et al. 2013 cloveski et al. 2014 cloveski et al. 2014 cloveski et al. 2017 cloveski et al. 2012 cloveski et al. 2017 cloveski et al. 2012 cloveski et al. 2017 cloveski et al. 2012 cloveski et al. 2014 cloveski et al. 2015 cloveski et al. 2012 cloveski et al. 2012	Foa et al. 1991					
a et al. 2005 1.36 0.18 .000 dovski et al. 2012 1.71 0.25 .000 sick et al. 2002 1.26 0.14 .000 sick et al. 2008 1.42 0.17 .000 irs et al. 2013 1.00 0.14 .000 ssault ES 1.33 0.10 .000 rlson et al. 1998 1.07 0.45 .017 aard et al. 2010 1.29 0.16 .000 rbes et al. 2012 1.11 0.27 .000 cash et al. 2011-1 2.14 0.66 .001 uch 2009 1.04 0.48 .031 uch et al. 2015 2.87 0.79 .000 orp et al. 2012 1.45 0.57 .011 erk et al. 2011 1.04 0.18 .000 ombat ES 1.23 0.12 .000 ukai et al. 2010 1.68 0.52 .001 pezzani et al. 2013 1.87 0.42 .000 villy and Spence 1999 1.05 0.45 .021 lers et al. 2014 2.11 0.38 .000 geberg et al. 2007 0.87 0.38 .023 e et al. 2007 0.87 0.38 .023 e et al. 2012 1.83 0.23 .000 piel et al. 2012 1.83 0.23 .000 piel et al. 2015 1.73 0.17 .000 wer et al. 2002 2.30 0.51 .000 lixed ES 1.74 0.12 .000 lixed ES 1.74 0.12 .000	Foa et al. 1999					.
Hovski et al. 2012 1.71 0.25 $.000$ sick et al. 2002 1.26 0.14 $.000$ sick et al. 2008 1.42 0.17 $.000$ irs et al. 2013 1.00 0.14 $.000$ ssault ES 1.33 0.10 $.000$ rlson et al. 1998 1.07 0.45 $.017$ ard et al. 2010 1.29 0.16 $.000$ rbes et al. 2012 1.11 0.27 $.000$ rcsah et al. 2011-1 2.14 0.66 $.001$ uch et al. 2015 2.87 0.79 $.000$ orp et al. 2012 1.45 0.57 $.011$ erk et al. 2011 1.04 0.18 $.000$ ombat ES 1.23 0.12 $.000$ ukai et al. 2010 1.68 0.52 $.001$ pezzani et al. 2013 1.87 0.42 $.000$ vivily and Spence 1999 1.05 0.45 $.021$ lers et al. 2007 0.87 0.38 $.023$ e et al. 2012 1.89 0.56 $.001$ cash et al. 2014 2.11 0.38 $.023$ e et al. 2002 1.89 0.56 $.001$ cash et al. 2015 1.73 0.17 $.000$ wer et al. 2002 2.30 0.51 $.000$ itad Random ES 1.43 0.15 $.000$	Foa et al. 2005					-
sick et al. 2002 1.26 0.14 .000 sick et al. 2008 1.42 0.17 .000 irs et al. 2013 1.00 0.14 .000 ssault ES 1.33 0.10 .000 rlson et al. 1998 1.07 0.45 .017 ard et al. 2010 1.29 0.16 .000 rbes et al. 2012 1.11 0.27 .000 icash et al. 2011-1 2.14 0.66 .001 uch 2009 1.04 0.48 .031 uch et al. 2015 2.87 0.79 .000 orp et al. 2012 1.45 0.57 .011 erk et al. 2011 1.04 0.18 .000 ombat ES 1.23 0.12 .000 ukai et al. 2010 1.68 0.52 .001 pezzani et al. 2013 1.87 0.42 .000 ivilly and Spence 1999 1.05 0.45 .021 lers et al. 2014 2.11 0.38 .000 ogberg et al. 2007 0.87 0.38 .023 e et al. 2007 0.87 0.38 .023 e et al. 2012 1.43 0.56 .001 icash et al. 2015 1.73 0.17 .000 wer et al. 2002 2.30 0.51 .000 lixed ES 1.74 0.12 .000 lixed ES 1.43 0.15 .000	Galovski et al. 2012					
sick et al. 2008 1.42 0.17 .000 irs et al. 2013 1.00 0.14 .000 ssault ES 1.33 0.10 .000 rlson et al. 1998 1.07 0.45 .017 aard et al. 2010 1.29 0.16 .000 rbes et al. 2012 1.11 0.27 .000 icash et al. 2011-1 2.14 0.66 .001 uch et al. 2015 2.87 0.79 .000 orp et al. 2012 1.45 0.57 .011 erk et al. 2011 1.04 0.18 .000 ombat ES 1.23 0.12 .000 ukai et al. 2010 1.68 0.52 .001 pezzani et al. 2013 1.87 0.42 .000 willy and Spence 1999 1.05 0.45 .021 lers et al. 2005 2.24 0.59 .000 geberg et al. 2007 0.87 0.38 .023 et al. 2012 1.83 0.23 .001 icash et al. 2011-2 3.34 1.32 .011 djam et al. 2012	Resick et al. 2002					ાન
irs et al. 2013 1.00 0.14 $.000$ ssault ES 1.33 0.10 $.000$ rlson et al. 1998 1.07 0.45 $.017$ aard et al. 2010 1.29 0.16 $.000$ rbes et al. 2012 1.11 0.27 $.000$ ccash et al. 2011-1 2.14 0.66 $.001$ uch 2009 1.04 0.48 $.031$ uch et al. 2015 2.87 0.79 $.000$ orp et al. 2012 1.45 0.57 $.011$ erk et al. 2011 1.04 0.18 $.000$ ombat ES 1.23 0.12 $.000$ ukai et al. 2010 1.68 0.52 $.001$ pezzani et al. 2013 1.87 0.42 $.000$ villy and Spence 1999 1.05 0.45 $.021$ lers et al. 2005 2.24 0.59 $.000$ lers et al. 2007 0.87 0.38 $.023$ e et al. 2012 1.89 0.56 $.001$ ccash et al. 2011-2 3.34 1.32 $.011$ djam et al. 2012 1.83 0.23 $.000$ wer et al. 2002 2.30 0.51 $.000$ lixed ES 1.74 0.12 $.000$ tal Random ES 1.43 0.15 $.000$	Resick et al. 2008	1.42	0.17			
ssault ES1.330.10.000rlson et al. 1998 1.07 0.45 0.17 aard et al. 2010 1.29 0.16 0.00 rbes et al. 2012 1.11 0.27 0.00 ccash et al. 2011-1 2.14 0.66 0.01 uch 2009 1.04 0.48 0.31 uch et al. 2015 2.87 0.79 0.00 oorp et al. 2012 1.45 0.57 0.11 erk et al. 2011 1.04 0.18 0.00 ombat ES 1.23 0.12 $.000$ ukai et al. 2010 1.68 0.52 0.01 pezzani et al. 2013 1.87 0.42 0.00 villy and Spence 1999 1.05 0.45 0.21 lers et al. 2005 2.24 0.59 0.00 lers et al. 2007 0.87 0.38 0.23 e et al. 2012 1.89 0.56 0.01 iccash et al. 2011-2 3.34 1.32 0.11 djam et al. 2012 1.83 0.23 0.00 piel et al. 2015 1.73 0.17 0.00 wer et al. 2002 2.30 0.51 0.00 lixed ES 1.74 0.12 $.000$ tal Random ES 1.43 0.15 0.00	Suirs et al. 2013					
rlson et al. 1998 1.07 0.45 $.017$ aard et al. 2010 1.29 0.16 $.000$ rbes et al. 2012 1.11 0.27 $.000$ acash et al. 2011-1 2.14 0.66 $.001$ uch 2009 1.04 0.48 $.031$ uch et al. 2015 2.87 0.79 $.000$ oor p et al. 2012 1.45 0.57 $.011$ erk et al. 2011 1.04 0.18 $.000$ ombat ES 1.23 0.12 $.000$ ukai et al. 2010 1.68 0.52 $.001$ pezzani et al. 2013 1.87 0.42 $.000$ willy and Spence 1999 1.05 0.45 $.021$ lers et al. 2005 2.24 0.59 $.000$ lers et al. 2007 0.87 0.38 $.023$ e et al. 2002 1.89 0.56 $.001$ acash et al. 2011-2 3.34 1.32 $.011$ djam et al. 2012 1.83 0.23 $.000$ wer et al. 2002 2.30 0.51 $.000$ tixed ES 1.74 0.12 $.000$ tal Random ES 1.43 0.15 $.000$	Assault ES					
ard et al. 2010 1.29 0.16 .000 rbes et al. 2012 1.11 0.27 .000 acash et al. 2011-1 2.14 0.66 .001 uch 2009 1.04 0.48 .031 uch et al. 2015 2.87 0.79 .000 orp et al. 2012 1.45 0.57 .011 erk et al. 2011 1.04 0.18 .000 ombat ES 1.23 0.12 .000 ukai et al. 2010 1.68 0.52 .001 pezzani et al. 2013 1.87 0.42 .000 willy and Spence 1999 1.05 0.45 .021 lers et al. 2005 2.24 0.59 .000 lers et al. 2014 2.11 0.38 .000 ogberg et al. 2007 0.87 0.38 .023 e et al. 2012 1.83 0.23 .000 icash et al. 2012 1.83 0.23 .000 piel et al. 2015 1.73 0.17 .000 wer et al. 2002 2.30 0.51 .000 tixed ES 1.4	Carlson et al. 1998					-
rbes et al. 2012 1.110.27.000iccash et al. $2011-1$ 2.140.66.001uch 20091.040.48.031uch et al. 2015 2.870.79.000oorp et al. 2012 1.450.57.011erk et al. 2011 1.040.18.000ombat ES1.230.12.000ukai et al. 2010 1.680.52.001pezzani et al. 2013 1.870.42.000willy and Spence 19991.050.45.021lers et al. 2005 2.240.59.000lers et al. 2007 0.870.38.023e et al. 2002 1.890.56.001iccash et al. 2012 1.830.23.000piel et al. 2012 1.830.23.000iccash et al. 2012 1.830.23.000piel et al. 2012 1.830.23.000iccash et al. 2002 2.300.51.000iccash et al. 2002 2.300.51.000iccash et al. 2002 2.300.51.000icash et al. 2002 2.300.51.000ic	Chard et al. 2010					
acash et al. 2011-1 2.14 0.66 $.001$ uch 2009 1.04 0.48 $.031$ uch et al. 2015 2.87 0.79 $.000$ oorp et al. 2012 1.45 0.57 $.011$ erk et al. 2011 1.04 0.18 $.000$ ombat ES 1.23 0.12 $.000$ ukai et al. 2010 1.68 0.52 $.001$ pezzani et al. 2013 1.87 0.42 $.000$ vvilly and Spence 1999 1.05 0.45 $.021$ lers et al. 2005 2.24 0.59 $.000$ lers et al. 2007 0.87 0.38 $.023$ e et al. 2012 1.83 0.23 $.000$ iccash et al. 2012 1.83 0.23 piel et al. 2015 1.73 0.17 $.000$ wer et al. 2002 2.30 0.51 $.000$ lixed ES 1.74 0.12 $.000$	Forbes et al. 2012	1.11	0.27			
uch 2009 1.04 0.48 .031 uch et al. 2015 2.87 0.79 .000 oorp et al. 2012 1.45 0.57 .011 erk et al. 2011 1.04 0.18 .000 ombat ES 1.23 0.12 .000 ukai et al. 2010 1.68 0.52 .001 pezzani et al. 2013 1.87 0.42 .000 willy and Spence 1999 1.05 0.45 .021 lers et al. 2005 2.24 0.59 .000 lers et al. 2014 2.11 0.38 .002 ogberg et al. 2007 0.87 0.38 .023 e et al. 2012 1.89 0.56 .001 iccash et al. 2012 1.83 0.23 .000 piel et al. 2015 1.73 0.17 .000 wer et al. 2002 2.30 0.51 .000 lixed ES 1.74 0.12 .000 tal Random ES 1.43 0.15 .000	Nacash et al. 2011-1	2.14	0.66			-
orp et al. 2012 1.450.57.011erk et al. 2011 1.040.18.000ombat ES1.230.12.000ukai et al. 2010 1.680.52.001pezzani et al. 2013 1.870.42.000ovilly and Spence 19991.050.45.021lers et al. 2005 2.240.59.000lers et al. 2014 2.110.38.000ogberg et al. 2007 0.870.38.023e et al. 2002 1.890.56.001djam et al. 2012 1.830.23.000piel et al. 2015 1.730.17.000wer et al. 2002 2.300.51.000Lixed ES1.740.12.000	Rauch 2009	1.04	0.48			
orp et al. 2012 1.450.57.011erk et al. 2011 1.040.18.000ombat ES1.230.12.000ukai et al. 2010 1.680.52.001pezzani et al. 2013 1.870.42.000ovilly and Spence 19991.050.45.021lers et al. 2005 2.240.59.000lers et al. 2014 2.110.38.000ogberg et al. 2007 0.870.38.023e et al. 2002 1.890.56.001icash et al. 2012 1.830.23.000piel et al. 2015 1.730.17.000wer et al. 2002 2.300.51.000Itxed ES1.740.12.000	Rauch et al. 2015	2.87	0.79	.000		
erk et al. 2011 1.04 0.18 .000 ombat ES 1.23 0.12 .000 ukai et al. 2010 1.68 0.52 .001 pezzani et al. 2013 1.87 0.42 .000 willy and Spence 1999 1.05 0.45 .021 lers et al. 2005 2.24 0.59 .000 lers et al. 2014 2.11 0.38 .000 ogberg et al. 2007 0.87 0.38 .023 e et al. 2002 1.89 0.56 .001 iccash et al. 2011-2 3.34 1.32 .011 djam et al. 2015 1.73 0.17 .000 wer et al. 2002 2.30 0.51 .000 Itxed ES 1.74 0.12 .000	Thorp et al. 2012	1.45	0.57			
ukai et al. 2010 1.68 0.52 .001 pezzani et al. 2013 1.87 0.42 .000 willy and Spence 1999 1.05 0.45 .021 lers et al. 2005 2.24 0.59 .000 lers et al. 2014 2.11 0.38 .000 ogberg et al. 2007 0.87 0.38 .023 e et al. 2002 1.89 0.56 .001 iccash et al. 2011-2 3.34 1.32 .011 djam et al. 2012 1.83 0.23 .000 piel et al. 2015 1.73 0.17 .000 wer et al. 2002 2.30 0.51 .000 Itxed ES 1.74 0.12 .000	Tuerk et al. 2011	1.04	0.18			-
ukai et al. 2010 1.68 0.52 .001 pezzani et al. 2013 1.87 0.42 .000 willy and Spence 1999 1.05 0.45 .021 lers et al. 2005 2.24 0.59 .000 lers et al. 2014 2.11 0.38 .000 ogberg et al. 2007 0.87 0.38 .023 e et al. 2002 1.89 0.56 .001 iccash et al. 2011-2 3.34 1.32 .011 djam et al. 2012 1.83 0.23 .000 piel et al. 2015 1.73 0.17 .000 wer et al. 2002 2.30 0.51 .000 Itxed ES 1.74 0.12 .000	Combat ES	1.23	0.12			_ ▲
pezzani et al. 2013 1.87 0.42 .000 evilly and Spence 1999 1.05 0.45 .021 lers et al. 2005 2.24 0.59 .000 lers et al. 2014 2.11 0.38 .000 ogberg et al. 2007 0.87 0.38 .023 e et al. 2002 1.89 0.56 .001 iccash et al. 2011-2 3.34 1.32 .011 djam et al. 2012 1.83 0.23 .000 piel et al. 2015 1.73 0.17 .000 wer et al. 2002 2.30 0.51 .000 Lixed ES 1.74 0.12 .000	Asukai et al. 2010	1.68				- I
willy and Spence 1999 1.05 0.45 .021 lers et al. 2005 2.24 0.59 .000 lers et al. 2014 2.11 0.38 .000 ogberg et al. 2007 0.87 0.38 .023 e et al. 2002 1.89 0.56 .001 ucash et al. 2011-2 3.34 1.32 .011 djam et al. 2012 1.83 0.23 .000 piel et al. 2015 1.73 0.17 .000 wer et al. 2002 2.30 0.51 .000 lixed ES 1.74 0.12 .000	Capezzani et al. 2013	1.87	0.42	.000		· ·
lers et al. 2014 2.11 0.38 .000 ogberg et al. 2007 0.87 0.38 .023 e et al. 2002 1.89 0.56 .001 acash et al. 2011-2 3.34 1.32 .011 djam et al. 2012 1.83 0.23 .000 piel et al. 2015 1.73 0.17 .000 wer et al. 2002 2.30 0.51 .000 lixed ES 1.74 0.12 .000	Devilly and Spence 1999	1.05	0.45	.021		
ogberg et al. 2007 0.87 0.38 .023 e et al. 2002 1.89 0.56 .001 acash et al. 2011-2 3.34 1.32 .011 djam et al. 2012 1.83 0.23 .000 piel et al. 2015 1.73 0.17 .000 wer et al. 2002 2.30 0.51 .000 Iixed ES 1.74 0.12 .000 tal Random ES 1.43 0.15 .000	Ehlers et al. 2005	2.24	0.59	.000		
ogberg et al. 2007 0.87 0.38 .023 e et al. 2002 1.89 0.56 .001 acash et al. 2011-2 3.34 1.32 .011 djam et al. 2012 1.83 0.23 .000 piel et al. 2015 1.73 0.17 .000 wer et al. 2002 2.30 0.51 .000 Iixed ES 1.74 0.12 .000 tal Random ES 1.43 0.15 .000	Ehlers et al. 2014	2.11	0.38	.000		
acash et al. 2011-2 3.34 1.32 .011 djam et al. 2012 1.83 0.23 .000 piel et al. 2015 1.73 0.17 .000 wer et al. 2002 2.30 0.51 .000 Iixed ES 1.74 0.12 .000 tal Random ES 1.43 0.15 .000	Hogberg et al. 2007	0.87	0.38			
djam et al. 2012 1.83 0.23 .000 piel et al. 2015 1.73 0.17 .000 wer et al. 2002 2.30 0.51 .000 Iixed ES 1.74 0.12 .000 tal Random ES 1.43 0.15 .000	Lee et al. 2002	1.89	0.56	.001		-
piel et al. 2015 1.73 0.17 .000 wer et al. 2002 2.30 0.51 .000 lixed ES 1.74 0.12 .000 tal Random ES 1.43 0.15 .000	Nacash et al. 2011-2	3.34	1.32	.011		
wer et al. 2002 2.30 0.51 .000 lixed ES 1.74 0.12 .000 tal Random ES 1.43 0.15 .000	Nidjam et al. 2012	1.83	0.23	.000		
Iixed ES 1.74 0.12 .000 tal Random ES 1.43 0.15 .000	Popiel et al. 2015	1.73	0.17	.000		
tal Random ES 1.43 0.15 .000	Power et al. 2002	2.30	0.51	.000		
	Mixed ES	1.74	0.12	.000		
-4.00 -2.00 0	Total Random ES	1.43	0.15	.000	I	1
				-4.00	-2.00	0

Figure 3.

Repeated Measures Trauma Type Subgroup Analysis. g = Hedges' g; SE = Standard Error; ES = effect size. Three studies were separated by trauma type for trauma type analyses. Two studies included some participants with non-combat traumas, but only the participants with combat trauma were included in the trauma type analysis due to small n in other trauma type categories (i.e., Rauch et al., 2009: n = 8; Thorp et al., 2012: n = 5). One study was separated by trauma type in trauma type analysis as follows: Nacash et al. (2011; n = 10) = Combat, Nacash et al. (2011; n = 5) = Mixed.

Study Name	g	SE	р	Hedges' <i>g</i> & 95% CI
Asukai et al. 2010	1.68	0.52	.001	
Capezzani et al. 2013	1.87	0.42	.000	
Devilly and Spence 1999	1.05	0.45	.021	
Ehlers et al. 2005	2.24	0.59	.000	
Ehlers et al. 2014	2.11	0.38	.000	
Feske 2008	1.42	0.53	.008	
Foa et al. 1991	1.05	0.44	.017	
Foa et al. 1999	1.95	0.42	.000	
Foa et al. 2005	1.36	0.18	.000	
Galovski et al. 2012	1.71	0.25	.000	
Hogberg et al. 2007	0.87	0.38	.023	
Lee et al. 2002-1	1.63	0.61	.007	
Nijdam et al. 2012	1.83	0.23	.000	
Popiel et al. 2015	1.73	0.17	.000	
Power et al. 2002	2.30	0.51	.000	
Resick et al. 2002	1.26	0.14	.000	
Resick et al. 2008	1.42	0.17	.000	
Civilian ES	1.55	0.08	.000	
Carlson et al. 1998	1.07	0.45	.017	
Chard et al. 2010	1.29	0.16	.000	
Forbes et al. 2012	1.11	0.27	.000	
Lee et al. 2002-2	2.59	1.17	.026	
Monson et al. 2006	1.40	0.30	.000	│ │ _∎-┥
Nacash et al. 2011	2.33	0.58	.000	
Rauch et al. 2009	1.04	0.48	.031	
Rauch et al. 2015	2.87	0.79	.000	
Suirs et al. 2013	1.00	0.14	.000	
Thorp et al. 2012	1.36	0.55	.013	
Tuerk et al. 2011	1.04	0.18	.000	
Military ES	1.22	0.10	.000	
Total Random ES	1.39	0.17	.000	
			-4.00	-2.00 0 2.00

Figure 4.

Repeated Measures Population Type Subgroup Analysis. g = Hedges' g; SE = Standard Error; ES = effect size. One study included military and civilian participants and therefore was separated by population for population type analyses. Lee et al. (2002) was separated by population type as follows: Lee et al. (2002-1; n = 4) = Military, Lee et al. (2002-2; n = 8) = Civilian.

$\mathbf{\Sigma}$
<u> </u>
-
-
2
0
0
_
\geq
01
<u>u</u>
=
<u> </u>
0
~
0
-
<u> </u>
$\overline{\mathbf{O}}$
<u> </u>

Author Manuscript

Author Manuscript

Table 1

Study Characteristics

Study Name	u	Intervention Type	PTSD Measure	Trauma Type	Population	Trial Type	Age (M)	Female (%)	Attrition (%)	Dx (%)	SAM
Asukai et al. 2010	12	PE	CAPS, IES-R	Mixed (Assault, Accident)	Civilian	RCT	29	87	25	NR	ITT
Capezzani et al. 2013	21	EMDR	IES-R	Mixed (Cancer)	Civilian	CCT	53	90	0	95	ITT
Carlson et al. 1998	10	EMDR	MS-Com, IES	Combat	Military	RCT	53	0	0	78	CA
Chard et al. 2010	104	CPT	CAPS, PCL-S	Combat	Military	UCT	45	0	31	51	ITT
Devilly and Spence 1999	11	EMDR	MS-Civ, IES, PSS, PTSD-I	Mixed (Sexual/Physical Assault, Accident, Disaster, War Zone)	Civilian	сст	40	72	55	36	CA
Ehlers et al. 2005	14	CJ	PSS, CAPS	Mixed (Accident, Assault, Witnessed Death)	Civilian	RCT	55	37	0	71	ITT
Ehlers et al. 2014	61	СТ	CAPS, PSS	Mixed (Assault, Accident, Disaster, Witnessed Death, Other)	Civilian	RCT	39	59	б	71	TTI
Feske 2008	6	PE	PSS	Assault	Civilian	RCT	43	100	31	NR	CA
Foa et al. 1991	10	PE	PSS	Assault	Civilian	RCT	32	100	29	40	CA
Foa et al. 1999	23	PE	PSS	Assault	Civilian	RCT	35	100	8	60	CA
Foa et al. 2005	79	PE	PSS	Assault	Civilian	RCT	31	100	34	NR	ITT
Forbes et al. 2012	30	CPT	CAPS, PCL-S	Combat	Military	RCT	53	4	30	38	ITT
Galovski et al. 2012	53	CPT	PSS, CAPS	Assault	Civilian	RCT	40	NR	26	92	ITT
Högberg et al. 2007	12	EMDR	IES	Mixed (Accident, Assault)	Civilian	RCT	43	21	0	67	CA
Lee et al. 2002	12	EMDR	SIP-I, IES	Mixed (Assault, Accident, Combat, and Witnessed Death)	Civilian, Military ^d	RCT	34	NR	×	83	CA
Monson et al. 2006	30	CPT	CAPS, PCL-S	NR^{a}	Military	RCT	54	10	20	40	TTI
Nacash et al. 2010	15	PE	PSS	Mixed ^c (Combat,Terror- related)	Military	RCT	34	NR	13	NR	TTI
Nijdam et al. 2012	70	EMDR	SIP-I, IES-R	Mixed (Assault, Accident, Disaster, War-related, Other)	Civilian	ССТ	38	51	36	66	ITT
Popiel et al. 2015	114	PE	PSS-SR	Mixed (Accident)	Civilian	CCT	40	21	18	99	ITT
Power et al. 2002	27	EMDR	SIP-SR, IES	Mixed (Accident, Assault, Traumatic Death, Real or Implied Physical Threat, Other)	Civilian	RCT	39	42	31	NR	CA

Study Name	u	Intervention Type	PTSD Measure	Trauma Type	Population	Trial Type	Age (M)	Female (%)	Attrition (%)	Dx (%) SAM	SAM
Rauch et al. 2009	10	PE	PSS	Mixed ^b (Combat; MST/ Assault)	Military	UCT	39	20	0	NR	TTI
Rauch et al. 2015	11	PE	CAPS	Combat	Military	CCT	32	8	39	NR	CA
Resick et al. 2002	124	PE, CPT	CAPS, PSS	Assault	Civilian	RCT	32	100	27	53	ITT
Resick et al. 2008	100	CPT	PSS, CAPS	Assault	Civilian	CCT	35	100	24	60	ITT
Schnurr et al. 2007^*	141	PE	CAPS, PCL-S	Mixed ^c (Assault, Combat, Other)	Military	RCT	44	100	38	39	TTI
Surís et al. 2013	52	CPT	CAPS, PCL-S	MST/Assault	Military	RCT	46	85	35	NR	ITT
Thorp et al. 2012	×	PE	CAPS, IES-R	Mixed ^b (Combat; MST; Accident)	Military	Quasi	63	0	0	88	CA
Tuerk et al. 2011	65	PE	PCL-M	Combat	Military	UCT	32	11	34	49	ΤΤ

 $M^{=}$ mean; % = percentage; Dx = PTSD diagnosis at posttreatment; SAM= statistical analysis method; ITT = intent to treat; CA = completer; PE = prolonged exposure; CPT = cognitive processing therapy; CT Scale for PTSD (-Combat or -Civilian); PCL (-S or -M) = Posttraumatic Stress Disorder Checklist (-Specific or -Military); PSS (-SR) = Posttraumatic Stress Scale Interview (-Self Report); PTSD-I = PTSD = cognitive therapy; EMDR = eye movement desensitization reprocessing; CAPS = Clinician Administered PTSD Scale; IES(-R) = Impact of Events Scale (-Revised); MS (-Com or -Civ) = Mississippi Interview; SIP (-I or -SR) = Structured Interview for PTSD (-Interview or -Self Report); NR = not reported. Note. lotal N = 1,228; PISU = post

 2 The study sample was excluded from trauma type analysis because trauma type was not indicated and author did not respond through correspondence.

J Anxiety Disord. Author manuscript; available in PMC 2020 October 01.

^bThe study sample included some participants with non-combat traumas, but only the participants with combat trauma were included in the trauma type analysis due to small n in other trauma type categories (Rauch et al., 2009: n = 8; Thorp et al., 2012: n = 5); ^c. The study sample was separated by trauma type in analysis for reasons described in the Methods section; studies with a trauma type category defined as "Mixed" without a superscript were not separated by trauma type in trauma type analysis.

dDenotes the study sample was separated by population type for population analysis.

* study was identified as an outlier based on SAM-D statistic.

Author Manuscript